NCM · Biotechnology

BioAtla, Inc. (BCAB) Stock

$3.40 +0.89% NCM: BCAB Healthcare

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers.

Valuation

MetricValue
Price$3.40
Market Cap$4.29M
P/E Ratio-0.08
P/B Ratio-0.14
P/S Ratio2.12
EPS (TTM)$-50.50
52-Week High$71.50
52-Week Low$3.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE166.67%
ROA-590.91%
ROCE416.45%
Gross Margin-2950.00%
Operating Margin-2950.00%
Net Margin-25.31%
Debt/Equity-0.16
Current Ratio0.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$11.0M$2.0M
Operating Profit$-96.0M$-108.0M$-130.0M$-74.0M$-59.0M
Net Profit$-95.0M$-105.0M$-123.0M$-70.0M$-60.0M
EPS$-138.00$-137.00$-129.00$-72.00$-50.50
Op Margin-38576.0%——-672.2%-2965.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$254.0M$226.0M$120.0M$52.0M$14.0M
Total Liabilities$44.0M$45.0M$49.0M$38.0M$50.0M
Cash$245.0M$216.0M$111.0M$49.0M$7.0M
Borrowings$5.0M$4.0M$2.0M$1.0M$6.0M

Latest News

Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal MT Newswires · May 18, 2026 Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-62.0M$-90.0M$-104.0M$-72.0M$-48.0M
Investing Cash Flow$-2.0M$-1.0M$0$0$0
Financing Cash Flow$-2.0M$0$0$0$-1.0M
Net Cash Flow$6.0M$-29.0M$-104.0M$-62.0M$-42.0M
Free Cash Flow$-63.0M$-91.0M$-104.0M$-72.0M$-48.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.18
FCF Yield-1119.53%
Quick Ratio0.36
Interest Coverage0.00
Return 1Y-78.38%
Return 3Y-96.84%
Return 5Y-99.78%

Ownership

Insiders Held5.46%
Institutions Held22.50%
Institutions Float Held23.80%
Institutional HolderSharesReport Date
Marshall Wace LLP277,6302026-03-31
Acorn Capital Advisors, LLC 108,1272026-03-31
Millennium Management Llc55,1332026-03-31
Vanguard Capital Management LLC32,9852026-03-31
Acadian Asset Management. LLC24,6782026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About BioAtla, Inc.

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

BioAtla, Inc. is led by CEO Jay Short, employs 61 people, headquartered in US, publicly traded since 2020.

BioAtla, Inc. (BCAB) stock trades at $3.40 with a market capitalization of $4.29M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of -0.14, price-to-sales of 2.12. Over the past 52 weeks the stock has ranged between $3.12 and $71.50, and currently trades 95.2% below its 52-week high.

On profitability, BioAtla, Inc. generates a return on equity (ROE) of 166.67% — well above the market average, a sign of a high-quality business, return on capital employed of 416.45%, an operating margin of -2950.00%, a net profit margin of -25.31%.

Official website: www.bioatla.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides